Grande Carolyn, Caparro Millie
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
Semin Oncol Nurs. 2005 Nov;21(4 Suppl 1):41-9. doi: 10.1016/j.soncn.2005.10.012.
To provide oncology nurses with an understanding of the differences between low-molecular-weight heparins and unfractionated heparin, key clinical trial data, and current treatment guidelines.
Primary and tertiary literature and the authors' clinical experience.
The latest American College of Chest Physicians guidelines recommend low-molecular weight heparin for at least the first 3 to 6 months of long-term treatment for most patients with cancer and deep vein thrombosis (DVT; grade 1A).
Anticoagulant therapy has been found to be the most effective form of treatment for venous thromboembolism in patients with cancer, and oncology nurses play a critical role in the choice of agents, the dispensing of drugs, and the monitoring of ongoing therapy. Vital to that role are an ability to differentiate among the available agents and apply the current practice guidelines based on the clinical trial data.
让肿瘤学护士了解低分子量肝素与普通肝素之间的差异、关键临床试验数据以及当前的治疗指南。
一级和三级文献以及作者的临床经验。
美国胸科医师学会最新指南建议，对于大多数患有癌症和深静脉血栓形成（DVT）的患者，在长期治疗的至少前3至6个月使用低分子量肝素（1A级）。
抗凝治疗已被证明是癌症患者静脉血栓栓塞最有效的治疗形式，肿瘤学护士在药物选择、给药以及持续治疗监测方面发挥着关键作用。该角色的关键在于能够区分可用药物，并根据临床试验数据应用当前的实践指南。
